


IN THE CLAIMS

Please amend the claims as follows:

Claim 1 (Currently Amended): A substituted methylene amide derivative of Formula

(I) :



as well as its geometrical isomers, its optically active forms as enantiomers, diastereomers and its racemate forms, as well as pharmaceutically acceptable salts and pharmaceutically active derivatives thereof, wherein

$R^1$  is CH-phenyl, CH-naphthyl, CH<sub>2</sub>-phenyl, or CH<sub>2</sub>-naphthyl ~~selected from the group consisting of (C<sub>1</sub>-C<sub>15</sub>)alkyl, (C<sub>2</sub>-C<sub>12</sub>)alkenyl, (C<sub>2</sub>-C<sub>12</sub>)alkynyl, aryl, heteroaryl, (3-8-membered) cycloalkyl or heterocycloalkyl, (C<sub>4</sub>-C<sub>12</sub>)alkyl-aryl or (C<sub>4</sub>-C<sub>12</sub>)alkyl-heteroaryl, (C<sub>2</sub>-C<sub>12</sub>)alkenyl-aryl or heteroaryl, (C<sub>2</sub>-C<sub>12</sub>)alkynyl-aryl or heteroaryl;~~

$R^{2a}$  and  $R^{2b}$  are each independently from each other selected from the group comprising or consisting of H or (C<sub>1</sub>-C<sub>12</sub>)alkyl;

Cy is a phenyl substituted by

a phenyl;


an oxadiazole group;

1 or 2 moieties selected from the group consisting of -NH-CO-R<sup>3</sup>, -SO<sub>2</sub>-NR<sup>3</sup>R<sup>3'</sup> and -CO-NR<sup>3</sup>R<sup>3'</sup> wherein R<sup>3</sup> and R<sup>3'</sup> are independently selected from H and (C<sub>1</sub>-C<sub>15</sub>)alkyl; or

B-R<sup>4</sup> wherein B is an ethynyl group and R<sup>4</sup> is a (C<sub>1</sub>-C<sub>12</sub>)alkyl phenyl.

an aryl, heteroaryl, cycloalkyl or heterocycle group,

with the proviso that the following compounds are excluded:



Claims 2-4 (Cancelled).

Claim 5 (Currently Amended): The substituted methylene amide derivative according to claim 1 [[4]], wherein  $\text{R}^{3'}$  is H and  $\text{R}^3$  is selected from the group consisting of diphenyl-ethyl, dodecyl, octyl, 4-pentyl-benzyl, 4-phenoxy-phenethyl, ethyl-thiophen-2-yl, pentadecyl, tridecyl, hexyloxy-phenyl or (2-ethyl)-hexyl.

Claims 6-11 (Cancelled).


Claim 12 (Currently Amended): The substituted methylene amide derivative according to claim 1 wherein:

$R^{2a}$  and  $R^{2b}$  are each H;

~~$R^1$  is  $\text{CH}_2\text{-A}$ , with A being phenyl or thienyl, optionally substituted by cyano, halogen, methoxy, hydroxy, phenoxy,  $\text{NO}_2$ , trifluoromethyl; Cy is a thienyl, phenyl or biphenyl being substituted by  $\text{SO}_2\text{R}^3$ ,  $\text{CO-NR}^3\text{R}^{3'}$  in which  $\text{R}^{3'}$  is H and  $\text{R}^3$  is  $(\text{C}_7\text{-C}_{12})$ alkyl.~~

Claim 13 (Cancelled).

Claim 14 (Currently Amended): A substituted methylene amide derivative of Formula (I'):



wherein

~~$R^1$  is selected from the group consisting of phenyl, benzyl, phenethyl, 1-methylbenzyl which may be substituted by  $(\text{C}_1\text{-C}_6)$ alkyl group or a cycloalkyl group;~~

~~Cy is a phenyl or a biphenyl group substituted with a moiety selected from the group consisting of  $\text{-NH-CO-R}^3$ ,  $\text{-CO-NH-R}^3$ , or an oxadiazole group substituted with  $\text{R}^3$ , wherein  $\text{R}^3$  is  $(\text{C}_7\text{-C}_{15})$ alkyl.~~

15-26 (Canceled).

Claim 27 (Currently Amended): A pharmaceutical composition comprising at least one substituted methylene amide derivative according to claim 1 and a pharmaceutically acceptable carrier, diluent or excipient thereof.

Claim 28 (Currently Amended): The pharmaceutical composition according to claim 27 further comprising at least one supplementary drug ~~selected from the group consisting of insulin, aldose reductase inhibitors, alpha-glucosidase inhibitors, sulfonyl-urea agents, biguanides, thiazolidines, PPARs agonists, c-Jun Kinase or GSK-3 inhibitors.~~

Claim 29-41 (Cancelled)

Claim 42 (New) A pharmaceutical composition comprising at least one substituted methylene amide according to claim 5 and a pharmaceutically acceptable carrier, diluent or excipient thereof.

Claim 43 (New) A pharmaceutical composition comprising at least one substituted methylene amide according to claim 12 and a pharmaceutically acceptable carrier, diluent or excipient thereof.

Claim 44 (New) A pharmaceutical composition comprising at least one substituted methylene amide according to claim 14 and a pharmaceutically acceptable carrier, diluent or excipient thereof.

Claim 45 (New) A pharmaceutical composition comprising at least one substituted methylene amide according to claim 15 and a pharmaceutically acceptable carrier, diluent or excipient thereof.

Claim 46 (New) { {4-[(4-hexylphenyl)ethynyl]benzyl} [4-(trifluoromethyl)benzyl]amino }-(oxo)acetic acid.

Claim 47 (New) A pharmaceutical composition comprising at least one substituted methylene amide according to claim 46 and a pharmaceutically acceptable carrier, diluent or excipient thereof.